Article Information
History
- July 1, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mark J. Mulligan1 (mark.mulligan{at}nyulangone.org),
- Kirsten E. Lyke2 (klyke{at}som.umaryland.edu),
- Nicholas Kitchin3 (nicholas.kitchin{at}pfizer.com),
- Judith Absalon4,12 (judith.absalon{at}pfizer.com),
- Alejandra Gurtman4 (alejandra.gurtman{at}pfizer.com),
- Stephen P. Lockhart5 (stephen.p.lockhart{at}pfizer.com),
- Kathleen Neuzil2 (kneuzil{at}som.umaryland.edu),
- Vanessa Raabe1 (vanessa.raabe{at}nyulangone.org),
- Ruth Bailey5 (ruth.bailey{at}pfizer.com),
- Kena A. Swanson4 (kena.swanson{at}pfizer.com),
- Ping Li6 (ping.li4{at}pfizer.com),
- Kenneth Koury4 (kenneth.koury{at}pfizer.com),
- Warren Kalina7 (warren.kalina{at}pfizer.com),
- David Cooper4 (david.cooper1{at}pfizer.com),
- Camila Fonter-Garfias8 (crfontes{at}utmb.edu),
- Pei-Yong Shi8 (peshi{at}utmb.edu),
- Ozlem Tuereci9 (oezlem.tuereci{at}biontech.de),
- Kristin R. Tompkins4 (kristin.tompkins{at}pfizer.com),
- Edward E. Walsh10 (edward.walsh{at}rochesterregional.org),
- Robert Frenck11 (robert.frenck{at}cchmc.org),
- Ann R. Falsey10 (ann.falsey{at}rochesterregional.org),
- Philip R. Dormitzer4 (philip.dormitzer{at}pfizer.com),
- William C. Gruber4 (bill.gruber{at}pfizer.com),
- Ugur Sahin9 (sahin{at}uni-mainz.de) and
- Kathrin U. Jansen4 (kathrin.jansen{at}pfizer.com)
- 1 New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY;
- 2 University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD;
- 3 Pfizer, Inc., Hurley, UK;
- 4 Pfizer, Inc., Pearl River, NY;
- 5 Pfizer, Inc., Hurley, UK;
- 6 Pfizer, Inc., Collegeville, PA;
- 7 Pfizer, Inc. Pearl River, NY;
- 8 University of Texas Medical Branch, Galveston, TX;
- 9 BioNTech, Mainz, Germany;
- 10 University of Rochester and Rochester General Hospital, Rochester, NY;
- 11 Cincinnati Children Hospital, Cincinnati, OH
- ↵* Corresponding author; email: judith.absalon{at}pfizer.com
Posted July 01, 2020.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
